Sweden · Delayed Price · Currency is SEK BioGaia AB Statistics
Total Valuation
BioGaia AB has a market cap or net worth of SEK 11.69 billion. The enterprise value is 11.25 billion.
| Market Cap | 11.69B |
| Enterprise Value | 11.25B |
Important Dates
The last earnings date was Friday, July 17, 2026.
| Earnings Date | Jul 17, 2026 |
| Ex-Dividend Date | May 8, 2026 |
Share Statistics
BioGaia AB has 101.16 million shares outstanding.
| Current Share Class | 98.50M |
| Shares Outstanding | 101.16M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 5.52% |
| Owned by Institutions (%) | 38.22% |
| Float | 84.12M |
Valuation Ratios
The trailing PE ratio is 33.71 and the forward PE ratio is 27.15.
| PE Ratio | 33.71 |
| Forward PE | 27.15 |
| PS Ratio | 7.40 |
| PB Ratio | 10.62 |
| P/TBV Ratio | 12.37 |
| P/FCF Ratio | 39.02 |
| P/OCF Ratio | 37.15 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 24.21, with an EV/FCF ratio of 37.54.
| EV / Earnings | 32.39 |
| EV / Sales | 7.12 |
| EV / EBITDA | 24.21 |
| EV / EBIT | 25.55 |
| EV / FCF | 37.54 |
Financial Position
The company has a current ratio of 4.44
| Current Ratio | 4.44 |
| Quick Ratio | 2.11 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 89.59 |
Financial Efficiency
Return on equity (ROE) is 30.78% and return on invested capital (ROIC) is 57.70%.
| Return on Equity (ROE) | 30.78% |
| Return on Assets (ROA) | 19.77% |
| Return on Invested Capital (ROIC) | 57.70% |
| Return on Capital Employed (ROCE) | 39.15% |
| Weighted Average Cost of Capital (WACC) | 6.01% |
| Revenue Per Employee | 6.30M |
| Profits Per Employee | 1.38M |
| Employee Count | 243 |
| Asset Turnover | 1.14 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, BioGaia AB has paid 97.22 million in taxes.
| Income Tax | 97.22M |
| Effective Tax Rate | 21.87% |
Stock Price Statistics
The stock price has increased by +16.30% in the last 52 weeks. The beta is 0.32, so BioGaia AB's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | +16.30% |
| 50-Day Moving Average | 122.08 |
| 200-Day Moving Average | 112.34 |
| Relative Strength Index (RSI) | 43.62 |
| Average Volume (20 Days) | 152,221 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioGaia AB had revenue of SEK 1.58 billion and earned 347.23 million in profits. Earnings per share was 3.43.
| Revenue | 1.58B |
| Gross Profit | 1.15B |
| Operating Income | 437.86M |
| Pretax Income | 444.44M |
| Net Income | 347.23M |
| EBITDA | 464.67M |
| EBIT | 440.23M |
| Earnings Per Share (EPS) | 3.43 |
Balance Sheet
The company has 446.27 million in cash and no debt, with a net cash position of 446.27 million or 4.41 per share.
| Cash & Cash Equivalents | 446.27M |
| Total Debt | n/a |
| Net Cash | 446.27M |
| Net Cash Per Share | 4.41 |
| Equity (Book Value) | 1.10B |
| Book Value Per Share | 10.88 |
| Working Capital | 728.98M |
Cash Flow
In the last 12 months, operating cash flow was 314.80 million and capital expenditures -15.13 million, giving a free cash flow of 299.67 million.
| Operating Cash Flow | 314.80M |
| Capital Expenditures | -15.13M |
| Depreciation & Amortization | 16.72M |
| Net Borrowing | -6.78M |
| Free Cash Flow | 299.67M |
| FCF Per Share | 2.96 |
Margins
Gross margin is 73.01%, with operating and profit margins of 27.70% and 21.97%.
| Gross Margin | 73.01% |
| Operating Margin | 27.70% |
| Pretax Margin | 28.12% |
| Profit Margin | 21.97% |
| EBITDA Margin | 29.40% |
| EBIT Margin | 27.85% |
| FCF Margin | 18.96% |
Dividends & Yields
This stock pays an annual dividend of 4.00, which amounts to a dividend yield of 3.46%.
| Dividend Per Share | 4.00 |
| Dividend Yield | 3.46% |
| Dividend Growth (YoY) | -42.03% |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | 3.46% |
| Earnings Yield | 2.97% |
| FCF Yield | 2.56% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for BioGaia AB is 152.50, which is 31.92% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 152.50 |
| Price Target Difference | 31.92% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 10.54% |
| EPS Growth Forecast (3Y) | 17.37% |
Stock Splits
The last stock split was on May 18, 2022. It was a forward split with a ratio of 5.
| Last Split Date | May 18, 2022 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |